APPENDICES. A systematic review and economic model of the ...

More documents

Recommendations

Info

208 Appendix 12 Core symptoms Educational performance Quality of life Adverse events Not reported Problem Behaviour Checklist (parents): side-effects (Mean, SD) (1 = not at all; 4 = very much) Scores for: poor appetite/awake at night/headaches/ ‘tummyaches’/’side-effects of drugs’ Before drug: 1.48 (0.87)/1.79 (1.01) /1.79 (0.73) /1.93 (1.80)/1.34 (0.81) MPH: 1.83 (0.97)/1.76 (0.91) /1.52 (0.51) /1.62 (0.62)/1.59 (0.78) DEX: 1.93 (1.03)/1.86 (0.92) /1.52 (0.78) /1.52 (0.57)/1.59 (0.87) Poor appetite: placebo > MPH, p < 0.05; placebo > DEX, p < 0.01 ‘Tummyaches’: DEX > placebo, p < 0.05 Davids’ Hyperkinetic Rating Scale (parents): poor schoolwork Before drug: 4.62 (1.29) MPH: 3.69 (1.28) DEX: 3.79 (1.18) Significance of difference not reported Problem Behaviour Checklist (parents): total score (mean, SD) Before drug: 190.07 (37.91) MPH: 152.28 (34.79) DEX: 146.97 (36.63) MPH = DEX, not significant Davids’ Hyperkinetic Rating Scale (teachers): poor schoolwork Before drug: 4.62 (1.29) MPH: 3.83 (1.28) DEX: 3.93 (1.33) MPH = DEX, not significant Problem Behaviour Checklist (parents): hyperactivity Before drug: 24.31 (4.66) MPH: 18.21 (5.61) DEX: 17.21 (5.45) Significance of difference not reported Problem Behaviour Checklist (parents): inattentive unproductiveness Before drug: 15.83 (4.32) MPH: 11.83 (3.79) DEX: 11.38 (3.39) Significance of difference not reported Conners’ Teachers’ Behaviour Problem Checklist: total score Before drug: 91.52 (16.70) MPH: 73.55 (22.35) DEX: 70.26 (18.33) MPH = DEX, not significant Conners’ Teachers’ Behaviour Problem Checklist: hyperactivity Before drug: 23.10 (4.50) MPH: 16.83 (5.50) DEX: 16.17 (4.64) Significance of difference not reported Conners’ Teachers’ Behaviour Problem Checklist: day-dreaming and inattention Before drug: 14.97 (3.27) MPH: 12.10 (3.53) DEX: 12.03 (3.94) Significance of difference not reported Davids’ Hyperkinetic Rating Scale (parents): total score Before drug: 30.76 (3.40) MPH: 25.41 (5.19) DEX: 25.31 (5.57) MPH = DEX, not significant continued
Core symptoms Educational performance Quality of life Adverse events Davids’ Hyperkinetic Rating Scale (parents): hyperactivity Before drug: 5.24 (0.91) MPH: 4.31 (1.23) DEX: 4.28 (1.07) Significance of difference not reported Davids’ Hyperkinetic Rating Scale (parents): short attention span Before drug: 5.14 (0.99) MPH: 3.90 (1.01) DEX: 4.21 (0.94) Significance of difference not reported. Davids’ Hyperkinetic Rating Scale (parents): impulsiveness Before drug: 5.38 (0.78) MPH: 4.10 (1.21) DEX: 4.17 (1.04) Significance of difference not reported Davids’ Hyperkinetic Rating Scale (teachers): total score Before drug: 29.03 (5.14) MPH: 23.14 (7.08) DEX: 22.38 (7.20) MPPH = DEX, not significant © Queen’s Printer and Controller of HMSO 2006. All rights reserved. Health Technology Assessment 2006; Vol. 10: No. 23 Davids’ Hyperkinetic Rating Scale (teachers): hyperactivity Before drug: 5.28 (1.03) MPH: 3.83 (1.49) DEX: 3.90 (1.54) Significance of difference not reported Davids’ Hyperkinetic Rating Scale (teachers): short attention span Before drug: 4.86 (1.41) MPH: 3.97 (1.18) DEX: 3.79 (1.35) Significance of difference not reported Davids’ Hyperkinetic Rating Scale (teachers): impulsiveness Before drug: 5.03 (1.12) MPH: 3.93 (1.28) DEX: 3.90 (1.42) Significance of difference not reported continued 209
Page 1 and 2:
Appendices A systematic review and
Page 3 and 4:
Clinical effectiveness information
Page 5 and 6:
Searches for systematic reviews in
Page 7 and 8:
19. methyl phenidate.mp. 20. methyl
Page 9 and 10:
43. attention deficit$.mp. 44. 42 o
Page 11 and 12:
MEDLINE in-process and other non-in
Page 13 and 14: PsycINFO (1967-July 2004) Searched:
Page 15 and 16: next aminopropane) or dynaphenyl or
Page 17 and 18: or ritaline or riphenidate or rital
Page 19: System for Information on Grey Lite
Page 22 and 23: 166 Appendix 2 S hyperkinetic S imp
Page 24 and 25: 168 Appendix 2 19. (eq5d or eq 5d o
Page 26 and 27: 170 Appendix 2 14. (person trade of
Page 28 and 29: 172 Appendix 3 Reference Reason for
Page 31: Appendix 4 © Queen’s Printer and
Page 34 and 35: 178 Appendix 5 8. Was the statistic
Page 36 and 37: 180 Appendix 6 Cost-effectiveness R
Page 38 and 39: 182 Appendix 7 Appropriateness of m
Page 40 and 41: 184 Appendix 7 Sensitivity analysis
Page 42 and 43: 186 Appendix 7 Sensitivity analysis
Page 44 and 45: 188 Appendix 8 Probability cost-eff
Page 47 and 48: Appendix 10 © Queen’s Printer an
Page 49 and 50: Health state Responder to ATX, no s
Page 51 and 52: Health state Responder to IR-MPH, R
Page 53 and 54: Health state Responder to ER-MPH, R
Page 55: #Baseline shift random effects mode
Page 58 and 59: 202 Appendix 12 Study Intervention
Page 62 and 63: 206 Appendix 12 Core symptoms Educa
Page 114 and 115:
258 Appendix 12 Study Intervention
Page 116 and 117:
260 Appendix 12 Core symptoms Educa
Page 118 and 119:
Page 120 and 121:
Page 122 and 123:
Page 124 and 125:
Page 126 and 127:
Page 128 and 129:
Page 130 and 131:
Page 132 and 133:
Page 134 and 135:
Page 136 and 137:
Page 138 and 139:
Page 140 and 141:
Page 142 and 143:
Page 144 and 145:
Page 146 and 147:
Page 148 and 149:
Page 150 and 151:
Page 152 and 153:
Page 154 and 155:
Page 156 and 157:
Page 158 and 159:
Page 160 and 161:
Page 162 and 163:
Page 164 and 165:
Page 166 and 167:
Page 168 and 169:
Page 170 and 171:
Page 172 and 173:
Page 174 and 175:
Page 176 and 177:
Page 178 and 179:
Page 180 and 181:
Page 182 and 183:
Page 184 and 185:
Page 186 and 187:
Page 188 and 189:
Page 190 and 191:
Page 192 and 193:
Page 194 and 195:
Page 196 and 197:
Page 198 and 199:
Page 200 and 201:
Page 202 and 203:
Page 204 and 205:
Page 206 and 207:
Page 208 and 209:
Page 210 and 211:
Page 212 and 213:
Page 214 and 215:
Page 216 and 217:
Page 218 and 219:
Page 220 and 221:
Page 222:
366 Appendix 13 Study characteristi
show all

APPENDICES. A systematic review and economic model of the ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?